Tvardi Therapeutics Will Present in New York City
The biopharmaceutical firm will highlight its pipeline of STAT3-targeting therapies on October 20.
Updated on Oct. 14, 2026 in Healthcare
Tvardi Therapeutics management will deliver a corporate presentation at Chardan's 10th Annual Healthcare Conference in New York City. The presentation is scheduled for October 20, 2026, at 1:30 PM ET.
Why it matters
The company, based in Houston, uses the investor conference to discuss its progress in clinical-stage drug development. Executives will also engage in meetings with registered conference attendees to share corporate updates.
The firm is currently managing a Phase 1 healthy volunteer study of TTI-109 and a Phase 1b/2 clinical trial of TTI-101 for hepatocellular carcinoma. The 10th Annual Healthcare Conference serves as the platform for these operational updates.
The players
Tvardi Therapeutics
A clinical-stage biopharmaceutical company headquartered in Houston that focuses on STAT3-targeting small molecule therapies.
Chardan
A global investment bank that hosts an annual healthcare conference to connect biopharmaceutical firms with the investor community.
The details
Tvardi Therapeutics focuses on developing oral small molecule therapies that target STAT3. Management intends to use the session to outline ongoing research and future plans for TTI-109 in treating gastrointestinal diseases.
Timeline
October 20, 2026, at 1:30 PM ET.
Market Landscape
Participation in long-running industry events like the 10th Annual Healthcare Conference allows clinical-stage firms to maintain visibility among institutional investors. This follows a broader trend of private and public biotechs leveraging high-profile conferences to build momentum for upcoming funding rounds.
Investors and stakeholders monitoring the company will gain insight into the clinical trajectory of its lead candidates. These updates provide essential information regarding the company's timeline for future drug trials and capital requirements.
The takeaway
Investors should monitor the company's clinical pipeline closely as it works toward future gastrointestinal disease research. Clear communication of regulatory milestones remains a key driver for long-term development stability.
Further reading
For broader trends in medical research and industry events, see Healthcare.
